{"id":5361,"date":"2026-07-07T15:15:43","date_gmt":"2026-07-07T15:15:43","guid":{"rendered":"https:\/\/tradertideinsights.com\/?p=5361"},"modified":"2026-07-07T15:15:43","modified_gmt":"2026-07-07T15:15:43","slug":"crinetics-stocks-surge-after-vertex-agrees-to-10b-cash-buyout","status":"publish","type":"post","link":"https:\/\/tradertideinsights.com\/?p=5361","title":{"rendered":"Crinetics stocks surge after Vertex agrees to $10B cash buyout"},"content":{"rendered":"
<\/div>\n

Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company<\/a>in a deal valued at approximately $10 billion.<\/p>\n

The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.<\/p>\n

The acquisition sparked a sharp rally in CRNX stock.<\/p>\n

CRNX shares climbed nearly 100% in pre-market trading on Tuesday to around $83.69.<\/p>\n

Vertex shares, meanwhile, declined modestly following the announcement.<\/p>\n

The transaction comes amid a wave of pharmaceutical industry acquisitions, as large drugmakers seek to strengthen their development pipelines by acquiring smaller biotechnology companies with promising therapies.<\/p>\n

Vertex targets endocrinology growth<\/h2>\n

According to a joint press release, <\/a>Vertex expects Crinetics’ portfolio, including its approved acromegaly treatment Palsonify and investigational therapy Atumelnant, to contribute an estimated $5 billion in peak annual sales.<\/p>\n

Crinetics focuses on therapies for endocrine disorders.<\/p>\n

The company markets Palsonify, a once-daily oral treatment approved by the US Food and Drug Administration in September for acromegaly, a rare hormonal disorder caused in most cases by a noncancerous pituitary gland tumour that leads to excessive growth hormone production during adulthood.<\/p>\n

The disease can result in enlargement of the face, jaw, hands, and feet, along with symptoms including joint pain, headaches, and nausea. <\/p>\n

Crinetics said Palsonify works by lowering insulin-like growth factor to help alleviate these symptoms.<\/p>\n

The company’s pipeline also includes Atumelnant, a once-daily oral treatment under development for congenital adrenal hyperplasia (CAH), a group of inherited disorders affecting the adrenal glands.<\/p>\n

The condition leads to excessive production of male sex hormones known as androgens.<\/p>\n

Patients with CAH are commonly treated with high-dose glucocorticoids, which are associated with multiple side effects.<\/p>\n

Crinetics is developing Atumelnant as an alternative treatment approach.<\/p>\n

The company also said the therapy has demonstrated potential in treating Cushing’s syndrome, a rare hormonal disorder characterised by excessive cortisol levels that can cause rapid weight gain, muscle weakness, bruising and high blood pressure.<\/p>\n

CEO highlights strategic fit<\/h2>\n

Vertex Chief Executive Officer Reshma Kewalramani described the acquisition as strategically aligned with the company’s long-term growth plans.<\/p>\n

“Its focus on serious diseases in specialty markets with significant unmet need, well-understood causal human biology, and potentially best-in-class medicines could deliver transformative benefit to patients,” she said in a statement.<\/p>\n

Kewalramani added that Vertex intends to build on its experience in rare genetic diseases to continue expanding the commercial potential of Palsonify.<\/p>\n

Vertex has established its business around treatments for cystic fibrosis and has also expanded into gene-editing therapies through its partnership with CRISPR Therapeutics.<\/p>\n

Premium reflects pipeline potential<\/h2>\n

Crinetics closed at slightly above $42 per share before the announcement, meaning Vertex’s offer represents a premium of more than 100%.<\/p>\n

According to the companies, the acquired portfolio could generate approximately $5 billion in peak annual sales.<\/p>\n

Vertex reported total revenue of $12 billion last year, making the acquisition a significant addition to its long-term growth strategy.<\/p>\n

Market analysts also viewed the strategic rationale positively.<\/p>\n

Citi analyst Geoff Meacham said the acquisition aligns well with Vertex’s existing strengths in specialty diseases and biologically targeted medicines.<\/p>\n

“The fit is clear, given existing expertise in specialty markets, serious diseases, causal biology, and measurable biomarkers. The $5 billion peak sales framing adds another route to sustain double-digit topline growth.”<\/p>\n

Meacham maintained a Buy rating on Vertex and set a price target of $585, indicating further upside from the stock’s previous closing level.<\/p>\n

<\/h2>\n

The post Crinetics stocks surge after Vertex agrees to $10B cash buyout<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech companyin a deal valued at approximately $10 billion.The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.The acquisition sparked a sharp rally in CRNX stock.CRNX shares climbed nearly…<\/p>\n","protected":false},"author":1,"featured_media":5362,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-5361","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/5361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5361"}],"version-history":[{"count":0,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/5361\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/media\/5362"}],"wp:attachment":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}